மூன்றாவது இணைந்த மருத்துவமனை இல் சூரியன் யத் சென் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hong Kong Baptist University  A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has thepotential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV). The peptide-linked drug, which is responsive to the acidic environment found in tumours, is the first known agent to have successfully targeted two viral proteins that are simultaneously produced by EBV. It also offers a new strategy by increasing the uptake of anti-cancer drugs in tumour cells, thus allowing the application of lower drug dosages which helps reduce treatment side effects and health risks. The research results were published in the international academic journal

Hong kongHong lokGary wong ka leungThird affiliated hospital at sun yat sen universityHong kong polytechnic universityChemical technologyIncu bio program of the hong kong scienceBp innomed limitedHead of the department chemistryAsian fund for cancer researchTechnology parkProfessor of the department applied biologyProfessor of the department chemistryHong kong baptist university ledProfessor gary wong ka leungAssistant professor